CR20210602A - Compuestos de pirrolidina - Google Patents
Compuestos de pirrolidinaInfo
- Publication number
- CR20210602A CR20210602A CR20210602A CR20210602A CR20210602A CR 20210602 A CR20210602 A CR 20210602A CR 20210602 A CR20210602 A CR 20210602A CR 20210602 A CR20210602 A CR 20210602A CR 20210602 A CR20210602 A CR 20210602A
- Authority
- CR
- Costa Rica
- Prior art keywords
- sub
- och
- compounds
- formula
- pyrrolidine compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19382477 | 2019-06-07 | ||
| PCT/US2020/035825 WO2020247429A1 (en) | 2019-06-07 | 2020-06-03 | Pyrrolidine compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20210602A true CR20210602A (es) | 2022-01-06 |
Family
ID=66821161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20210602A CR20210602A (es) | 2019-06-07 | 2020-06-03 | Compuestos de pirrolidina |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US11286249B2 (enExample) |
| EP (1) | EP3980409A1 (enExample) |
| JP (5) | JP6940717B2 (enExample) |
| KR (3) | KR102720992B1 (enExample) |
| CN (1) | CN114008021B (enExample) |
| AU (1) | AU2020287599B2 (enExample) |
| BR (1) | BR112021023347A2 (enExample) |
| CL (1) | CL2021003202A1 (enExample) |
| CO (1) | CO2021016295A2 (enExample) |
| CR (1) | CR20210602A (enExample) |
| DO (1) | DOP2021000254A (enExample) |
| EA (1) | EA202193007A1 (enExample) |
| EC (1) | ECSP21088515A (enExample) |
| IL (2) | IL288174B2 (enExample) |
| JO (1) | JOP20210319B1 (enExample) |
| MA (1) | MA56115A (enExample) |
| MX (2) | MX2021014913A (enExample) |
| MY (1) | MY200810A (enExample) |
| PE (1) | PE20220134A1 (enExample) |
| PH (1) | PH12021553062A1 (enExample) |
| SA (1) | SA521431048B1 (enExample) |
| SG (1) | SG11202113244UA (enExample) |
| UA (1) | UA128540C2 (enExample) |
| WO (1) | WO2020247429A1 (enExample) |
| ZA (1) | ZA202109251B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023078333A1 (zh) | 2021-11-03 | 2023-05-11 | 上海拓界生物医药科技有限公司 | 一种取代的苯丙酸衍生物及其用途一种取代的苯丙酸衍生物及其用途 |
| EP4469435A1 (en) * | 2022-01-26 | 2024-12-04 | Eli Lilly and Company | Pyrrolidine compounds |
| US20260234125A1 (en) * | 2023-03-24 | 2026-08-13 | Shanghai Jingxin Biomedical Co., Ltd. | Cyclic amine derivative, and composition and use thereof |
| WO2024217537A1 (zh) * | 2023-04-21 | 2024-10-24 | 深圳信立泰药业股份有限公司 | 一种叔胺类化合物及其制备方法和医药用途 |
| TW202444710A (zh) | 2023-05-11 | 2024-11-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種脂蛋白化合物晶型及其製備方法 |
| CN122167331A (zh) | 2023-05-19 | 2026-06-09 | 深圳信立泰药业股份有限公司 | 一种磺酰胺类化合物及其制备方法和医药用途 |
| IL324569A (en) | 2023-06-30 | 2026-01-01 | Lilly Co Eli | Therapeutic uses and doses of lp(a) disrupter compounds |
| JP2026524960A (ja) | 2023-07-21 | 2026-07-24 | イーライ リリー アンド カンパニー | Ｌｐ（ａ）低下活性を有するピペリジン化合物 |
| KR20260041098A (ko) | 2023-07-21 | 2026-03-26 | 일라이 릴리 앤드 캄파니 | Lp(a) 저하 활성을 갖는 피롤리딘 화합물 |
| CN121548567A (zh) | 2023-07-21 | 2026-02-17 | 伊莱利利公司 | 具有Lp(a)降低活性的哌啶、吗啉和四氢哒嗪化合物 |
| KR20260041097A (ko) | 2023-07-21 | 2026-03-26 | 일라이 릴리 앤드 캄파니 | Lp(a) 저하 활성을 갖는 피롤리딘 화합물 |
| CN119490445A (zh) * | 2023-08-15 | 2025-02-21 | 深圳信立泰药业股份有限公司 | 一种酰基类化合物及其制备方法和医药用途 |
| CN122535600A (zh) * | 2023-11-17 | 2026-08-07 | 上海翊石医药科技有限公司 | 一种取代的2-(吡咯烷-3-基)乙酸的衍生物及其制备方法和用途 |
| CN122270439A (zh) * | 2023-11-20 | 2026-06-23 | 上海齐鲁制药研究中心有限公司 | 一种多环类衍生物、其制备方法和应用 |
| WO2025237188A1 (zh) * | 2024-05-14 | 2025-11-20 | 石家庄以岭药业股份有限公司 | 一种LP(a)抑制剂化合物及其应用 |
| WO2025255324A1 (en) * | 2024-06-06 | 2025-12-11 | Lapis Therapeutics, Inc. | Inhibitors of lipoprotein(a) assembly |
| CN121627662A (zh) * | 2024-09-05 | 2026-03-10 | 成都康弘药业集团股份有限公司 | 芳基丙酸化合物及其制备方法与用途 |
| WO2026061518A1 (zh) * | 2024-09-23 | 2026-03-26 | 上海京新生物医药有限公司 | 一种环状胺衍生物的固体形式、制备方法及药物组合物 |
| WO2026098459A1 (zh) * | 2024-11-06 | 2026-05-15 | 上海翊石医药科技有限公司 | 一种取代的2-(吡咯烷-3-基)乙酸衍生物的晶型及其制备方法和用途 |
| US20260130887A1 (en) * | 2024-11-14 | 2026-05-14 | Eli Lilly And Company | Oral compositions comprising lp(a) inhibitor compounds |
| WO2026108936A1 (zh) * | 2024-11-20 | 2026-05-28 | 深圳信立泰药业股份有限公司 | 一种化合物a可药用盐以及包含该化合物a可药用盐的药物组合物 |
| WO2026108938A1 (zh) * | 2024-11-20 | 2026-05-28 | 深圳信立泰药业股份有限公司 | 一种化合物a或其盐的无定型以及包含该无定形的药物组合物 |
| WO2026119122A1 (zh) * | 2024-12-02 | 2026-06-11 | 上海喆邺生物科技有限公司 | 一种苯丙酸衍生物及其医药用途 |
| WO2026130543A1 (zh) * | 2024-12-20 | 2026-06-25 | 上海维亚聃诚创业孵化器管理有限公司 | 多芳香环化合物、其组合物及用途 |
| WO2026145708A1 (zh) * | 2025-01-02 | 2026-07-09 | 上海喆邺生物科技有限公司 | 一种芳香酸类化合物及其医药用途 |
| CN121135622A (zh) * | 2025-04-11 | 2025-12-16 | 柴永帅 | 杂环化合物及其药物组合物和应用 |
| CN121609698B (zh) * | 2026-01-30 | 2026-06-02 | 山东京新药业有限公司 | 一种莫伐培林及中间体的制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2685325B1 (fr) * | 1991-12-20 | 1994-02-04 | Adir Cie | Nouveaux derives de pyrrolidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| US7371777B2 (en) | 2001-08-17 | 2008-05-13 | Eisai Co., Ltd. | Cyclic compound and PPAR agonist |
| AU2003300438A1 (en) * | 2003-12-24 | 2005-08-03 | Esperion Therapeutics, Inc. | Ether compounds and compositions for cholesterol management and related uses |
| US7705177B2 (en) | 2003-12-24 | 2010-04-27 | Esperion Therapuetics, Inc. | Ketone compounds and compositions for cholesterol management and related uses |
| KR101133862B1 (ko) | 2007-07-27 | 2012-04-06 | 에프. 호프만-라 로슈 아게 | Ｔａａｒ 리간드로서의 2-아제티딘메테인아민 및 2-피롤리딘메테인아민 |
| JP2019505508A (ja) | 2016-02-03 | 2019-02-28 | シャンハイ ハイヤン ファーマシューティカル テクノロジー カンパニー リミテッドＳｈａｎｇｈａｉ Ｈａｉｙａｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏ．， Ｌｔｄ． | 複素環置換ｎ−スルホニルベンズアミド誘導体、その製造方法および医薬における使用 |
| CN112321475B (zh) | 2020-11-13 | 2022-06-10 | 四川大学 | 一种γ-氨基酸类似物及其合成方法 |
-
2020
- 2020-06-03 KR KR1020247002433A patent/KR102720992B1/ko active Active
- 2020-06-03 PE PE2021002037A patent/PE20220134A1/es unknown
- 2020-06-03 EA EA202193007A patent/EA202193007A1/ru unknown
- 2020-06-03 CR CR20210602A patent/CR20210602A/es unknown
- 2020-06-03 UA UAA202106553A patent/UA128540C2/uk unknown
- 2020-06-03 WO PCT/US2020/035825 patent/WO2020247429A1/en not_active Ceased
- 2020-06-03 CN CN202080041924.XA patent/CN114008021B/zh active Active
- 2020-06-03 PH PH1/2021/553062A patent/PH12021553062A1/en unknown
- 2020-06-03 US US17/056,144 patent/US11286249B2/en active Active
- 2020-06-03 SG SG11202113244UA patent/SG11202113244UA/en unknown
- 2020-06-03 KR KR1020227043106A patent/KR102629923B1/ko active Active
- 2020-06-03 KR KR1020217040065A patent/KR102477481B1/ko active Active
- 2020-06-03 AU AU2020287599A patent/AU2020287599B2/en active Active
- 2020-06-03 MY MYPI2021007256A patent/MY200810A/en unknown
- 2020-06-03 BR BR112021023347A patent/BR112021023347A2/pt unknown
- 2020-06-03 MX MX2021014913A patent/MX2021014913A/es unknown
- 2020-06-03 IL IL288174A patent/IL288174B2/en unknown
- 2020-06-03 JP JP2021505713A patent/JP6940717B2/ja active Active
- 2020-06-03 EP EP20747210.1A patent/EP3980409A1/en active Pending
- 2020-06-03 MA MA056115A patent/MA56115A/fr unknown
-
2021
- 2021-09-02 JP JP2021143227A patent/JP7508422B2/ja active Active
- 2021-11-18 ZA ZA2021/09251A patent/ZA202109251B/en unknown
- 2021-11-30 CO CONC2021/0016295A patent/CO2021016295A2/es unknown
- 2021-12-01 JO JOJO/P/2021/0319A patent/JOP20210319B1/ar active
- 2021-12-01 CL CL2021003202A patent/CL2021003202A1/es unknown
- 2021-12-03 MX MX2025001789A patent/MX2025001789A/es unknown
- 2021-12-07 EC ECSENADI202188515A patent/ECSP21088515A/es unknown
- 2021-12-07 SA SA521431048A patent/SA521431048B1/ar unknown
- 2021-12-07 DO DO2021000254A patent/DOP2021000254A/es unknown
-
2022
- 2022-02-15 US US17/671,806 patent/US12441714B2/en active Active
-
2024
- 2024-06-18 JP JP2024098153A patent/JP7658014B2/ja active Active
-
2025
- 2025-03-26 JP JP2025052039A patent/JP2025098178A/ja active Pending
- 2025-06-23 IL IL321703A patent/IL321703B2/en unknown
- 2025-07-11 US US19/267,125 patent/US20260055086A1/en active Pending
-
2026
- 2026-04-23 JP JP2026071768A patent/JP2026126294A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20210319B1 (ar) | مركبات بيروليدين | |
| MX2025011447A (es) | Inhibidores de kras | |
| MX2025000642A (es) | Compuestos macrociclicos para el tratamiento de cancer | |
| WO2021147236A9 (zh) | 取代氨基丙酸酯类化合物在治疗SARS-CoV-2感染中的应用 | |
| CL2024000067A1 (es) | Compuestos antivirales | |
| MX2022010011A (es) | Inhibidores de prmt5 novedosos. | |
| CR20200488A (es) | Péptidos macrocíclicos contra actinetobacter baumannii | |
| MX2025008327A (es) | Composiciones y metodos para el tratamiento de trastornos del snc | |
| PH12021551256A1 (en) | Pantetheine derivatives and uses thereof | |
| EA202092168A1 (ru) | Применение фавипиравира в лечении коронавирусной инфекции | |
| MX2025010256A (es) | Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno | |
| EP4316504A3 (en) | Compounds | |
| DOP2025000090A (es) | Métodos de tratamiento del cáncer usando derivados de isoquinolina o 6-aza-quinolina | |
| MX2024012967A (es) | Derivados de piridina para el tratamiento de los trastornos psiquiatricos | |
| PH12021552953A1 (en) | Tricyclic compounds | |
| MX2024003930A (es) | Moduladores de trpml, sus composiciones y metodos de uso. | |
| JOP20240119A1 (ar) | مشتقات نافثيريدينون لمعالجة مرض أو اضطراب | |
| MX2023002539A (es) | Metodos para tratar enfermedades o afecciones mediadas por fosfodiesterasa iv (pde iv). | |
| WO2024168106A3 (en) | Modulators of trpml, their compositions and methods of use | |
| MX2024012739A (es) | Inhibidores de atr | |
| JOP20250073A1 (ar) | مركبات سلفوكسيمين كمثبط دياسيتيلاز هيستون 6، وتركيبة صيدلانية تشتمل عليها | |
| GEAP202516798A (en) | Auristatin linker-payloads, pharmaceutical compositions, and uses thereof | |
| MX2021014941A (es) | Inhibidores de dopamina-b-hidroxilasa. |